[1] |
Yao JC,Hassan M,Phan A, et al.One hundred years after "carcinoid" :epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States.Journal of clinical oncology, 2008, 26(18): 3063-3072.
|
[2] |
Modlin IM,Lye KD,Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors.Cancer, 2003, 97(4): 934-959.
|
[3] |
Ito T,Sasano H,Tanaka M, et al.Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.Journal of gastroenterology, 2010, 45(2): 234-243.
|
[4] |
Maggard MA,Connell JB,Ko CY.Updated population-based review of carcinoid tumors.Annals of Surgery, 2004, 240(1): 117-122.
|
[5] |
Onaitis MW,Kirshbom PM,Hayward TZ, et al.Gastrointestinal carcinoids:characterization by site of origin and hormone production.Ann Surg, 2000, 232(4): 549-556.
|
[6] |
Ahlman H,Nilsson O,Olausson M. Interventional treatment of the carcinoid syndrome.Neuroendocrinology, 2004, 80(1): 67-73.
|
[7] |
Glancy DG,Pullyblank AM,Thomas MG.The role of colonoscopic endoanal ultrasound scanning(EUS)in selecting patients suitable for resection by transanal endoscopic microsurgery(TEM). Colorectal disease:the official journal of the Association of Coloproctology of Great Britain and Ireland, 2005, 7(2): 148-150.
|
[8] |
Murray SE,Lloyd RV,Sippel RS, et al.Clinicopathologic characteristics of colonic carcinoid tumors.The Journal of surgical research, 2013, 184(1): 183-188.
|
[9] |
Pavel M,Baudin E,Couvelard A, et al.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrinology, 2012, 95(2): 157-176.
|
[10] |
Boo YJ,Park SS,Kim JH, et al.Gastric neuroendocrine carcinoma:clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.Journal of surgical oncology, 2007, 95(2): 110-117.
|
[11] |
Matsushita M,Takakuwa H,Nishio A. Management of rectal carcinoid tumors.Gastrointestinal endoscopy, 2003, 58(4): 641.
|
[12] |
Caplin M,Sundin A,Nillson O, et al.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms:colorectal neuroendocrine neoplasms.Neuroendocrinology, 2012, 95(2): 88-97.
|
[13] |
Sauven P,Ridge JA,Quan SH, et al.Anorectal carcinoid tumors.Is aggressive surgery warranted?Ann Surg, 1990, 211(1): 67-71.
|
[14] |
Maire F,Hammel P,Kianmanesh R, et al.Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery, 2009, 145(1): 69-75.
|
[15] |
Oberg K,Akerstrom G,Rindi G, et al.Neuroendocrine gastroenteropancreatic tumours:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology:official journal of the European Society for Medical Oncology / ESMO, 2010, 21(5): 223-227.
|
[16] |
Mc Entee GP,Nagorney DM,Kvols LK, et al.Cytoreductive hepatic surgery for neuroendocrine tumors.Surgery, 1990, 108(6): 1091-1096.
|
[17] |
Fendrich V,Bartsch DK.Surgical treatment of gastrointestinal neuroendocrine tumors.Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie, 2011, 396(3): 299-311.
|
[18] |
Sun W,Lipsitz S,Catalano P, et al.Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors:Eastern Cooperative Oncology Group Study E1281.Journal of clinical oncology:official journal of the American Society of Clinical Oncology, 2005, 23(22): 4897-4904.
|
[19] |
Ekeblad S,Sundin A,Janson ET, et al.Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.Clinical cancer research:an official journal of the American Association for Cancer Research, 2007, 13(10): 2986-2991.
|
[20] |
Anthony LB,Strosberg JR,Klimstra DS, et al.The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors(nets):well-differentiated nets of the distal colon and rectum.Pancreas, 2010, 39(6): 767-774.
|
[21] |
Strosberg JR,Coppola D,Klimstra DS, et al.The NANETS consensus guidelines for the diagnosis and management of poorly differentiated(high-grade)extrapulmonary neuroendocrine carcinomas.Pancreas, 2010, 39(6): 799-800.
|
[22] |
Rinke A,Muller HH,Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors:a report from the PROMID Study Group.Journal of clinical oncology:official journal of the American Society of Clinical Oncology, 2009, 27(28): 4656-4663.
|
[23] |
Yao JC,Shah MH,Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors.The New England journal of medicine, 2011, 364(6): 514-523.
|
[24] |
Raymond E,Dahan L,Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.The New England journal of medicine, 2011, 364(6): 501-513.
|
[25] |
Castellano D,Bajetta E,Panneerselvam A, et al.Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors:a subgroup analysis of the phase III RADIANT-2 study.The oncologist, 2013, 18(1): 46-53.
|
[26] |
Kulke MH,Lenz HJ,Meropol NJ, et al.Activity of sunitinib in patients with advanced neuroendocrine tumors.Journal of clinical oncology, 2008, 26(20): 3403-3410..
|
[27] |
Kwekkeboom DJ,Krenning EP,Lebtahi R, et al.ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors:peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.Neuroendocrinology, 2009, 90(2): 220-226.
|